Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7906 to 7920 of 8398 results

  1. Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]

    Discontinued Reference number: GID-TA11467

    Technology appraisal guidance
    Discontinued

  2. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development Reference number: GID-TA11500 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    Discontinued Reference number: GID-TA11074

    Technology appraisal guidance
    Discontinued

  4. Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]

    In development Reference number: GID-TA11606 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    Discontinued Reference number: GID-TA11146

    Technology appraisal guidance
    Discontinued

  6. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    Discontinued Reference number: GID-TA11277

    Technology appraisal guidance
    Discontinued

  7. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Discontinued Reference number: GID-TA11486

    Technology appraisal guidance
    Discontinued

  8. Pegcetacoplan for treating geographic atrophy [ID4041]

    Discontinued Reference number: GID-TA11351

    Technology appraisal guidance
    Discontinued

  9. Abicipar pegol for treating wet age-related macular degeneration [ID1533]

    In development Reference number: GID-TA10511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    In development Reference number: GID-TA11365 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    In development Reference number: GID-TA11021 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

    In development Reference number: GID-TA10774 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242) and bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).

    Withdrawn guidance

  14. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).

    Withdrawn guidance

  15. Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG484)

    This guidance has been updated and replaced by NICE HealthTech guidance 770.

    HealthTech guidance
    Published
    29 August 2018